Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Achaogen, Inc. (NASDAQ: AKAO).

Full DD Report for AKAO

You must become a subscriber to view this report.

Recent News from (NASDAQ: AKAO)

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc...
Source: SeekingAlpha
Date: May, 16 2018 03:55
Lucky Seven: Achaogen Likely To Bounce Back
The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C...
Source: SeekingAlpha
Date: May, 14 2018 08:19
Achaogen: Explicating The Prospects Of C-Scape
Long ago, Ben Graham taught me that ‘Price is what you pay; value is what you get.’ Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar investment for opportun...
Source: SeekingAlpha
Date: May, 13 2018 06:36
Achaogen: A Long-Term Holding With Tremendous Prospects
Most people are too fretful, they worry too much. Success means being very patient, but aggressive when it’s time. - Charlie Munger Achaogen (NASDAQ: AKAO ) is a stellar investing opportunity that suffered a temporary depreciation and thereby became a significant bargain with mu...
Source: SeekingAlpha
Date: May, 11 2018 02:50
Daily Insider Ratings Round Up 5/7/18: TSLA, TEGP, CVS, NHF, FLDM, AKAO, EYES, MDB
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: May, 09 2018 09:36
Achaogen: In The Middle Of A Temporary Difficulty There Is A Stellar Opportunity
Be fearful when others are greedy and greedy when others are fearful. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar bioscience that is quite volatile. Investors who are not the faint of heart can accumulate shares after the recent pullback for the potential to earn multiple fo...
Source: SeekingAlpha
Date: May, 09 2018 02:19
Blog Exposure - Lexicon Pharma's New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical Therapeutics
Stock Monitor: Achaogen Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ), all you need to do is sign up now by clicking the following link
Date: May, 08 2018 07:50
Iterum Therapeutics Plans $92 Million IPO
Quick Take Iterum Therapeutics ( ITRM ) intends to raise $92 million in an IPO from the sale of its common stock, according to an S-1 regulatory filing . The firm is a late clinical-stage biopharma developing treatments for urinary tract and intra-abdominal infections. ITRM is enhanci...
Source: SeekingAlpha
Date: May, 07 2018 12:02
Achaogen After Ad Comm
Always forgive your enemies; nothing annoys them so much .” ― Oscar Wilde Late last Tuesday, Achaogen ( AKAO ) got a mixed result from the Ad Comm Panel around its primary drug candidate Plazomicin. The good news was the panel voted unanimously in a 15-0 vote to recommend...
Source: SeekingAlpha
Date: May, 07 2018 10:38
Achaogen's (AKAO) CEO Blake Wise On Q1 2018 Results - Earnings Call Transcript
Achaogen (AKAO) Q1 2018 Earnings Conference Call May 4, 2018, 08:30 AM ET Executives Gary Loeb - General Counsel Blake Wise - CEO Kenneth Hillan - President, Research and Development Janet Dorling - CCO Toby Schilke - CFO Analysts Stephen Willey - Stifel Ami Fadia - L...
Source: SeekingAlpha
Date: May, 04 2018 15:12


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AKAO.

About Achaogen, Inc. (NASDAQ: AKAO)

Logo for Achaogen, Inc. (NASDAQ: AKAO)

Not available


Contact Information



Current Share Structure

  • Market Cap: $562,645,142 - 05/11/2018
  • Issue and Outstanding: 44,725,369 - 02/23/2018


Recent Filings from (NASDAQ: AKAO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 25 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 24 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 14 2018



Daily Technical Chart for (NASDAQ: AKAO)

Daily Technical Chart for (NASDAQ: AKAO)

Stay tuned for daily updates and more on (NASDAQ: AKAO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AKAO)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKAO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AKAO and does not buy, sell, or trade any shares of AKAO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: